Therapeutic Management of Dermatomyositis: Statement Analysis
Direct Answer to Each Statement
Statement (b) is CORRECT: Methotrexate may be administered, and statement (e) is CORRECT: Hydroxychloroquine is indicated for certain cutaneous manifestations. Statement (d) is CORRECT: CPK is a key biochemical marker for monitoring (though LDH is less specific). Statements (a) and (c) are INCORRECT.
Detailed Analysis by Statement
Statement (a): IVIG as First-Line Treatment - INCORRECT
High-dose corticosteroids combined with methotrexate represent the established first-line treatment for dermatomyositis, not IVIG 1, 2. The consensus-based guidelines clearly specify starting with methylprednisolone pulse therapy (15-30 mg/kg/dose for 3 consecutive days) followed by oral prednisolone 1-2 mg/kg/day, combined with methotrexate 15-20 mg/m² weekly 1.
IVIG is reserved for:
- Refractory disease that fails to respond to corticosteroids and methotrexate 1, 2
- Severe disease with extensive extramuscular organ involvement 2
- Patients with contraindications to corticosteroids 3
While older case reports suggested IVIG as initial therapy 4, 5, these represent isolated experiences that contradict current consensus guidelines. The 2017 SHARE guidelines, representing expert consensus from systematic literature review, definitively position IVIG as second-line or adjunctive therapy 1.
Statement (b): Methotrexate Administration - CORRECT
Methotrexate is a cornerstone medication in dermatomyositis management and should be initiated at diagnosis alongside corticosteroids 1, 2. The recommended dosing is 15-20 mg/m² weekly, preferably administered subcutaneously for better bioavailability 1, 2.
Key points about methotrexate use:
- Started concurrently with corticosteroids at disease onset 1
- Acts as a steroid-sparing agent, allowing corticosteroid tapering 2
- Continued even when intensifying treatment for refractory disease 1
- Can be maintained long-term, with consideration for discontinuation only after minimum 1 year of remission off steroids 1
The evidence strongly supports methotrexate as standard of care across multiple guidelines 1, 2, 6.
Statement (c): Corticosteroids Not Administered - INCORRECT
This statement is fundamentally wrong. Corticosteroids ARE the primary first-line treatment for dermatomyositis 1, 2. The concern about steroid-induced myopathy does not contraindicate their use in dermatomyositis—the benefits far outweigh this theoretical risk in active inflammatory myopathy.
The treatment algorithm explicitly requires:
- High-dose methylprednisolone pulse therapy at diagnosis 1
- Followed by oral prednisolone 1-2 mg/kg/day 1, 2
- Gradual tapering based on clinical response 1
Common pitfall: Confusing steroid-induced myopathy (a rare complication) with the need to avoid corticosteroids entirely. In dermatomyositis, untreated inflammation causes far more muscle damage than potential steroid side effects. The key is using corticosteroids judiciously with a steroid-sparing agent like methotrexate to enable tapering 2.
Statement (d): CPK and LDH as Monitoring Markers - PARTIALLY CORRECT
CPK (creatine phosphokinase) is definitively a key biochemical marker for monitoring dermatomyositis activity 1, 2. The PRINTO criteria for inactive disease specify CPK ≤150 U/L as one of four variables 1.
However, there are important nuances:
- CPK is the primary muscle enzyme marker and correlates with muscle inflammation 2
- LDH is less specific and not emphasized in major guidelines as a primary monitoring tool 1
- CPK may not differentiate well between active and inactive disease in all patients 1
- Other markers like ferritin are important, especially in severe disease or with interstitial lung disease 7
The statement is technically correct but incomplete—CPK is the gold standard, while LDH has supporting but less specific value 2.
Statement (e): Hydroxychloroquine for Cutaneous Involvement - CORRECT
Hydroxychloroquine is specifically indicated for cutaneous manifestations of dermatomyositis 2, 8. The evidence supports its use at 200 mg twice daily (5 mg/kg) primarily for skin disease 2.
Key evidence:
- Improves cutaneous lesions that may not respond to corticosteroids alone 8
- Often used in milder cases characterized predominantly by rash 6
- Does not appear to benefit the myositis component 8
- Requires ophthalmologic monitoring for retinal toxicity, with baseline screening and annual follow-up starting within 5 years 2
Important caveat: Sun protection with SPF 50+ sunscreen is paramount and should accompany hydroxychloroquine therapy 1, 2. The drug label notes potential for concomitant use with methotrexate may increase adverse reactions, requiring monitoring 9.
Practical Treatment Algorithm
At diagnosis:
- Start methylprednisolone pulse 15-30 mg/kg × 3 days
- Begin oral prednisolone 1-2 mg/kg/day
- Add methotrexate 15-20 mg/m² weekly (subcutaneous preferred)
- Advise sun protection, calcium, and vitamin D
- Add hydroxychloroquine 200 mg twice daily if prominent cutaneous disease
If inadequate response at 3-6 months:
- Add IVIG 2 g/kg monthly, OR
- Add/change to mycophenolate mofetil, cyclosporine A, OR
- Consider biologics (rituximab, anti-TNF agents)
Monitoring:
- CPK levels (primary marker)
- Muscle strength assessment
- Skin disease activity
- Major organ involvement screening